ViiV Healthcare has filed a new drug application (NDA) in Japan for its fixed-dos anti-HIV treatment combination drug containing dolutegravir and lamivudine for treatment-naïve adult patients with HIV-1 infection, it said on September 13.The drug, known as Dovato, is a…
To read the full story
BUSINESS
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Leqembi Sustains Benefits in Early Alzheimer’s after 5 Years of Treatment
November 18, 2026
- Meiji Invests US$50 Million in Arcturus to Expand mRNA Collaboration
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





